This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Venkateswarlu, K.
Right arrow Articles by Kelly, S. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venkateswarlu, K.
Right arrow Articles by Kelly, S. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 04 1997, 748-751, Vol 41, No. 4
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Fluconazole tolerance in clinical isolates of Cryptococcus neoformans

K Venkateswarlu, M Taylor, NJ Manning, MG Rinaldi and SL Kelly
Department of Molecular Biology and Biotechnology, The University of Sheffield, United Kingdom.

Eleven isolates of Cryptococcus neoformans were investigated to determine the biochemical basis of their tolerance to fluconazole. The MICs of fluconazole for three isolates with low-level resistance were 3- to 6-fold higher than those for sensitive isolates, while the MICs for four isolates with high-level resistance were 100- to 200-fold higher than those for sensitive isolates. The level of ergosterol present in the isolates varied, and those which had relatively low levels of ergosterol were resistant to amphotericin B. Changes in the affinity of the target enzyme (sterol 14alpha-demethylase) and decreases in the cellular content of fluconazole seemed to be responsible for the resistance in isolates with low-level and high-level resistance, respectively.


This article has been cited by other articles:

  • Sionov, E., Chang, Y. C., Garraffo, H. M., Kwon-Chung, K. J. (2009). Heteroresistance to Fluconazole in Cryptococcus neoformans Is Intrinsic and Associated with Virulence. Antimicrob. Agents Chemother. 53: 2804-2815 [Abstract] [Full Text]  
  • Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., Monk, B. C. (2009). Efflux-Mediated Antifungal Drug Resistance. Clin. Microbiol. Rev. 22: 291-321 [Abstract] [Full Text]  
  • Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
  • Perkins, A., Gomez-Lopez, A., Mellado, E., Rodriguez-Tudela, J. L., Cuenca-Estrella, M. (2005). Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J Antimicrob Chemother 56: 1144-1147 [Abstract] [Full Text]  
  • Rodero, L., Mellado, E., Rodriguez, A. C., Salve, A., Guelfand, L., Cahn, P., Cuenca-Estrella, M., Davel, G., Rodriguez-Tudela, J. L. (2003). G484S Amino Acid Substitution in Lanosterol 14-{alpha} Demethylase (ERG11) Is Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical Isolate. Antimicrob. Agents Chemother. 47: 3653-3656 [Abstract] [Full Text]  
  • Yamazumi, T., Pfaller, M. A., Messer, S. A., Houston, A. K., Boyken, L., Hollis, R. J., Furuta, I., Jones, R. N. (2003). Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41: 267-272 [Abstract] [Full Text]  
  • Favre, B., Didmon, M., Ryder, N. S. (1999). Multiple amino acid substitutions in lanosterol 14{alpha}-demethylase contribute to azole resistance in Candida albicans. Microbiology 145: 2715-2725 [Abstract] [Full Text]  
  • Mondon, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I., Kwon-Chung, K. J. (1999). Heteroresistance to Fluconazole and Voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43: 1856-1861 [Abstract] [Full Text]  
  • Thompson, J. R., Douglas, C. M., Li, W., Jue, C. K., Pramanik, B., Yuan, X., Rude, T. H., Toffaletti, D. L., Perfect, J. R., Kurtz, M. (1999). A Glucan Synthase FKS1 Homolog in Cryptococcus neoformans Is Single Copy and Encodes an Essential Function. J. Bacteriol. 181: 444-453 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Jensen-Pergakes, K. L., Kennedy, M. A., Lees, N. D., Barbuch, R., Koegel, C., Bard, M. (1998). Sequencing, Disruption, and Characterization of the Candida albicans Sterol Methyltransferase (ERG6) Gene: Drug Susceptibility Studies in erg6 Mutants. Antimicrob. Agents Chemother. 42: 1160-1167 [Abstract] [Full Text]  
  • White, T. C., Marr, K. A., Bowden, R. A. (1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev. 11: 382-402 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»